Alligator Bioscience AB (publ) Interim Report January-March 2019
STOCKHOLM, April 17, 2019 /PRNewswire/ -- Significant events January-March
First patient dosed in Phase I clinical study of ATOR-1015.
New preclinical data presented demonstrating strong anti-tumor effects for the 4-1BB antibody ATOR-1017.
Alligator Bioscience launched RUBYtm, a novel concept in bispecific antibody formats.
Events after the end of the period
Tumor-localizing properties of ATOR-1015 demonstrated by live imaging.
New preclinical data for ATOR-1144 demonstrates potential for activation of both the innate and the adaptive immune system as well as direct anti-tumor effects.
Financial information
January-March 2019
Net sales, SEK 0.0 million (0.8)
Total operating costs SEK -46.7 million (-45.0)
Operating result, SEK -46.2 million (-44.0)
Earnings per share before and after dilution, SEK -0.62 (-0.59)
Cash flow for the period, SEK -34.3 million (0.8)
Cash and cash equivalents, including securities, SEK 402.9 million (436.4)
"This is a very exciting year for Alligator. We currently have two projects ? ADC-1013 and ATOR-1015 ? in clinical development. These projects will soon be joined by ATOR-1017," CEO Per Norlén comments.
Read the complete report in the pdf below.
The information was submitted for publication at 8:00 a.m. CEST on April 17, 2019.
Cecilia Hofvander Director IR & Communications [email protected] 046-540-82-06
Alligator Bioscience AB (publ) 556597-8201 Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden Phone +46-46-540-82-00 www.alligatorbioscience.com
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit www.alligatorbioscience.com.
ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.
TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to...
SysInformation Healthcare Services, LLC ("SysInformation"), d/b/a EqualizeRCM and 1st Credentialing, is providing notice of a recent data security event that may affect the security of information related to certain individuals. SysInformation is...
Scottie Resources Corp. ("Scottie" or the "Company") announces that it has granted 7,400,000 options to acquire common shares to certain directors, officers, and consultants to the Company. The options are exercisable at a price of $0.195 per...
DaVita Inc. , announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 2, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.
This call is...
As part of its ongoing mission to meet the growing need for emergency services in metro Atlanta, Grady Health System will build a freestanding emergency department in south Fulton County. This freestanding emergency department, built in partnership...
Digicann Ventures Ltd. ("Digicann" or the "Company") , a company focused on opportunities within and outside of the cannabis industry, announces that it has entered into an agreement with holders of the Company's 10.00% Senior Unsecured Convertible...